Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) discussed at a multidisciplinary immune-related adverse event (irAE) tumor board.

Authors: Kyle VanDommelen, Lesil Brihn, Cassandra Calabrese, Keren Zhou, Michael Smith MD, Mamoun Abdoh, Amy Kunchok, Jessica Philpott, Shilpa Junna, Gowri Kabbur, Itunu Owoyemi, Thach-Giao Truong, Shilpa Gupta, Halle C. F. Moore, Nathan A. Pennell, Wen Wee Ma, Pauline Funchain, Lucy Boyce Kennedy

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e24112

Source: Full article

---

Abstract

e24112